Shares of Aslan Pharmaceuticals ASLN were down 32% premarket on Thursday after the company released new data from a clinical study of eblasakimab, an atopic dermatitis treatment. Among patients treated with the highest dose of the monoclonal antibody once every four weeks, 63% achieved at least a 75% reduction in an eczema area and severity index, the company said in a release, compared to 31% on placebo. “This is the first time we’ve seen a once-a-month treatment option deliver competitive efficacy data, which would be a game-changer for patients” with atopic dermatitis, Dr. Eric Simpson, professor of medical dermatology…
